Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 7/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28691680 | 1.00 | FPR2 (0.39) | FPR2SCN9AAURKAPDPK1ATR | |
| SCHEMBL22773890 | 0.87 | KMO (0.40) | FPR2SCN9AAURKAPDPK1ATR | |
| SCHEMBL22773888 | 0.87 | KMO (0.40) | FPR2SCN9AAURKAPDPK1ATR | |
| SCHEMBL24263564 | 0.86 | FPR2 (0.36) | FPR2SCN9AATRMTORMDM2 | |
| SCHEMBL2487867 | 0.85 | ATR (0.47) | ATRMTORPIK3CAMALT1 | |
| SCHEMBL738648 | 0.85 | ATR (0.47) | ATRMTORPIK3CAMALT1 | |
| SCHEMBL2492704 | 0.85 | ATR (0.47) | ATRMTORPIK3CAMALT1 | |
| SCHEMBL28788260 | 0.80 | AURKA (0.41) | AURKAPDPK1ATRMTORPIK3CA | |
| SCHEMBL593003 | 0.80 | PIK3CB (0.48) | PIK3CAPIK3CBALDH1A1 | |
| SCHEMBL22773872 | 0.78 | AURKA (0.41) | FPR2SCN9AAURKAPDPK1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306623-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3983409-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008044-A | Pyridyl or pyrimidinyl MTOR kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020249652-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | FPR2 4828/4885SCN9A 2429/4885AURKA 647/4885 |
| US-20220306623-A1 | PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS | MTOR, RICTOR, RPTOR | FPR2 1991/4885SCN9A 3084/4885AURKA 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.